Skip to main content
Clinical Trials/NCT03743961
NCT03743961
Terminated
Not Applicable

Description the Geriatric Intervention Contribution on Quality of Life of Elderly Patients With Metastatic Neoplasia : Prospective Descriptive Non-comparative Cohort ( QUALI Cohort)

Institut de Cancérologie de la Loire1 site in 1 country28 target enrollmentNovember 21, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Systemic Treatment
Sponsor
Institut de Cancérologie de la Loire
Enrollment
28
Locations
1
Primary Endpoint
Level of quality of life
Status
Terminated
Last Updated
5 years ago

Overview

Brief Summary

The aim of this study is to describe the impact of : Geriatric intervention contribution on quality of life of elderly patients receiving systemic treatments for metastatic neoplasia

Detailed Description

Elderly cancer incidence increases exponentially with advancing age. However, elderly patients are largely underrepresented in cancer treatment trials. The geriatric population presents particular physical, mental, psychological or social specificities that may condition the prognosis especially for patients with metastatic neoplasia. Recently, the measurement of quality of life (QoL) in aging population is being recognized as an important part of clinical decision. It is therefore essential to set up prospective studies to evaluate the impact of oncogeriatric practices on the quality of life of elderly patients with metastatic neoplasia. The main objective of this prospective study is to describe the contribution of geriatric intervention on quality of life for for elderly (\> 75 years) with metastatic solid cancer receiving systemic treatment during the first 6 months of their therapeutic management.

Registry
clinicaltrials.gov
Start Date
November 21, 2018
End Date
July 2, 2020
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Institut de Cancérologie de la Loire
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient with solid metastatic neoplasia
  • 75 years old or more
  • Men or women
  • ECOG between 0 and 3
  • Patient receiving systemic antineoplasic treatment (chemotherapy, hormonotherapy, immunotherapy, targeted therapy)

Exclusion Criteria

  • Localized cancer
  • Patients already included in a study witch could modify quality of life
  • Patient unable to give their consent

Outcomes

Primary Outcomes

Level of quality of life

Time Frame: 6 months

Level of quality of life will be measured with the QoL Q30 (Quality Qf Life with 30 Questions)

Secondary Outcomes

  • Duration of hospitalizations(6 months)
  • Number of toxicities ( grade 3 and 4)(6 months)
  • number of hospitalizations(6 months)

Study Sites (1)

Loading locations...

Similar Trials